about
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe impact of taxanes on the management of genitourinary cancers.Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development.PD-1 and PD-L1 antibodies in cancer: current status and future directions.Atezolizumab in invasive and metastatic urothelial carcinoma.First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancyHigh Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial CarcinomaPembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experiencePD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical TrialsEfficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder CancerBMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinomaCurrent Status and Future Direction of Immunotherapy in Urothelial CarcinomaPivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyThe complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
P50
Q30275266-57F877E5-B5AD-4D30-9F08-D2389EF39F4EQ30277192-D2A5851A-1304-49E2-B0CD-74B1EE39CC0FQ38187840-E088823A-8CD3-4B31-AFF2-50EDA79CE404Q38424928-B5B3FFDB-517B-46C3-8DB5-65951FFD51D0Q38755931-EBBB918C-8F69-4CC0-ACFB-4FE3B2405205Q47673176-F5EA316C-3B20-4526-91C9-E43AACDC48BEQ47717093-58349F06-8306-499A-AC6A-8A9A6C598B4CQ53223167-4C90AE90-7438-4E83-81BE-101D9E1EF4C3Q57057521-3FFEB9FE-3C14-4138-BB01-B929FD75FF13Q63966161-678CB9AB-203F-4CC5-BD09-E73B40DDB55AQ64078499-B1A10459-A62D-49A1-A8CD-ADEA7A7B4B18Q90039852-61CD99BC-CD47-4254-BA7B-7EE8B80F52F8Q91386609-75AEDC75-AC47-489A-B79D-3128294CADD1Q91447532-50234351-593A-42FC-948C-A5B85D3BCF38Q91926451-2E45C29E-874B-4D5D-9F37-FFBE0F6ABF08Q92249195-1E7B66F8-2261-495B-A3E3-036543BB7D3EQ92705394-0E750757-2331-4A67-9879-8A5DD2EF6D84
P50
description
researcher
@en
wetenschapper
@nl
name
Arjun V Balar
@en
Arjun V Balar
@nl
type
label
Arjun V Balar
@en
Arjun V Balar
@nl
prefLabel
Arjun V Balar
@en
Arjun V Balar
@nl
P31
P496
0000-0003-3949-5656